Literature DB >> 11337551

Brain SPECT in neurology and psychiatry.

E E Camargo1.   

Abstract

Structural and functional images of the brain play an important role as powerful adjuncts in the management of an increasing number of neurologic and psychiatric diseases. Brain SPECT, in particular, with perfusion agents or with neuroreceptor imaging radiopharmaceuticals, is rapidly becoming a clinical tool in many places. For many neurologic and psychiatric conditions, this imaging modality has been used in diagnosis, prognosis assessment, evaluation of response to therapy, risk stratification, detection of benign or malignant viable tissue, and choice of medical or surgical therapy. The importance of this technique in nuclear medicine today should not be overlooked, particularly in cerebrovascular diseases, dementias, epilepsy, head injury, malignant brain tumors, movement disorders, obsessive-compulsive disorder, Gilles de la Tourette's syndrome, schizophrenia, depression, panic disorder, and drug abuse.

Entities:  

Mesh:

Year:  2001        PMID: 11337551

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  27 in total

1.  [Diagnostic value of multislice perfusion CT in dementia patients].

Authors:  F Streitparth; G Wieners; A Kämena; R J Schröder; H Stiepani; T Kokocinski; R Röttgen; E Steinhagen-Thiessen; R Lenzen-Grossimlimghaus; N Hidajat
Journal:  Radiologe       Date:  2008-02       Impact factor: 0.635

2.  Required time delay from 99mTc-HMPAO injection to SPECT data acquisition: healthy subjects and patients with rCBF pattern.

Authors:  Gerda Thomsen; Robin de Nijs; Esben Hogh-Rasmussen; Vibe Frokjaer; Claus Svarer; Gitte M Knudsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-10       Impact factor: 9.236

Review 3.  Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-04-10       Impact factor: 3.825

Review 4.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

Review 5.  Brain single-photon emission CT physics principles.

Authors:  R Accorsi
Journal:  AJNR Am J Neuroradiol       Date:  2008-06-26       Impact factor: 3.825

6.  Brain perfusion SPECT in patients with mild cognitive impairment and Alzheimer's disease: comparison of a semiquantitative and a visual evaluation.

Authors:  W Staffen; U Schönauer; H Zauner; I Spindler; A Mair; B Iglseder; G Bernroider; G Ladurner
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 7.  Brain imaging and networks in restless legs syndrome.

Authors:  Giovanni Rizzo; Xu Li; Sebastiano Galantucci; Massimo Filippi; Yong Won Cho
Journal:  Sleep Med       Date:  2016-08-29       Impact factor: 3.492

8.  Changes in regional cerebral blood flow demonstrated by 99mTc-HMPAO SPECT in euthymic bipolar patients.

Authors:  Atesci Figen Culha; Ozdel Osman; Yuksel Dogangün; Karadag Filiz; Kirac Suna; Oguzhanoglu Nalan Kalkan; Varma Gulfizar; Akdag Beyza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

9.  Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease.

Authors:  Naama Levy-Cooperman; Amer M Burhan; Shahryar Rafi-Tari; Maggie Kusano; Joel Ramirez; Curtis Caldwell; Sandra E Black
Journal:  J Psychiatry Neurosci       Date:  2008-05       Impact factor: 6.186

10.  Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.

Authors:  W Staffen; J Bergmann; U Schönauer; H Zauner; M Kronbichler; S Golaszewski; G Ladurner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.